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Background 
CRP is a marker of inflammation and is also a known cardiovascular risk factor. Patients with 
systemic lupus erythematosus (SLE) have moderately elevated CRP levels and develop organ 
damage , that includes an increased rate of cardiovascular events.  
Objective 
The aim of this study is to assess the role of CRP in damage accrual in SLE patients over 
time. 
Methods  
The Tromsø Lupus cohort is a longitudinal population-based study of all SLE patients from 
the two most northern counties in Norway. Patients fulfilled the American College of 
Rheumatology (ACR) classification criteria. At each visit, CRP, disease activity (SLEDAI) 
and SLICC/ACR Damage index (SDI) were recorded. In this study, each component of the 
SDI was analyzed individually. First time myocardial infarction as well as first and second 
time cerebrovascular accidents were also analyzed separately. Both mean and median CRP 
and SLEDAI were calculated for each patient. 
 
Results 
224 patients were followed for a median of 66 months, mean of 87,3 (+/- 88,8) months. 
Median and mean CRP are respectively 4,0 mg/l and 9,9 (+/- 15,8). The median and mean 
SLEDAI are respectively 2,6 and 3,8.  Median CRP was not correlated with median SLEDAI 
(p=0.646). Median and mean CRP were higher in patients with first time myocardial 
infarction (p=0.004) but were unrelated with cerebrovascular accidents (p=0.760). Median 
CRP can be used as a risk factor for myocardial infarction as demonstrated with the area 
under the receiver operating characteristic curve (AUC=0.719 (0.573-0.864; p=0,004)) 
(figure). The specificity is over 80% with a median CRP of 10,75 mg/l or higher.  
Median and mean CRP were higher in patients with increased overall cardiovascular, 
pulmonary damages as well as malignancy (respectively p=0.014, p=0,027, p=0,020), had 
borderline association with peripheral vascular damage and was inversely correlated with 
gastrointestinal damage (p=0.031). 
Conclusion 
Median CRP can be used to stratify the risk for myocardial infarction in SLE patients.  
Median CRP is a better marker than SLEDAI for damage accrual in SLE patients, possibly 
because SLEDAI score tends to decrease while damage accrual increases over time. 
 
Figure  
Receiver operating curve for median CRP as a marker for myocardial infarction risk. 
 
 
